Walleye Capital LLC Aldeyra Therapeutics, Inc. Transaction History

Walleye Capital LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$3.25 - $4.72 $46,046 - $66,872	14,168 New	14,168 $46,000
Q2 2022 Aug 08, 2022	SELL	$2.43 - $4.85 $101,214 - $202,012	-41,652 Closed	0 $0
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $1.02 Million - $1.62 Million	-314,209 Reduced 88.3%	41,652 $185,000
Q4 2021 Mar 03, 2022	BUY	$3.5 - $9.63 $1.25 Million - $3.43 Million	355,861 New	355,861 $1.42 Million
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $1.43 Million - $2.03 Million	-179,810 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$10.44 - $14.85 $1.88 Million - $2.67 Million	179,810 New	179,810 $2.04 Million

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $280M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Walleye Capital LLC, based on Form 13F filings with the SEC.

Stay updated on Walleye Capital LLC with notifications on news.